Relapse after treatment with Miltefosine for visceral Leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain

mBio

Volumn 4, Issue 5, 2013, Pages

  Rai, Keshav ^a,b   Cuypers, Bart ^b   Bhattarai, Narayan Raj ^b   Uranw, Surendra ^b   Berg, Maya ^a   Ostyn, Bart ^a   Dujardin, Jean Claude ^a,c   Rijal, Suman ^b   Vanaerschot, Manu ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; MILTEFOSINE; STIBOGLUCONATE SODIUM;

ARTICLE; BANGLADESH; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; HEALTH PROGRAM; HUMAN; IN VITRO STUDY; INDIA; LEISHMANIA DONOVANI; METACYCLOGENESIS; NEPAL; NONHUMAN; PARASITE CLEARANCE; PARASITE CONTROL; PARASITE ISOLATION; PARASITE LOAD; PARASITE VIRULENCE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REINFECTION; VISCERAL LEISHMANIASIS;

LEISHMANIA DONOVANI; NASO HEXACANTHUS; PROTOZOA;

ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; PHOSPHORYLCHOLINE; RECURRENCE; VIRULENCE;

EID: 84887194451     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00611-13     Document Type: Article

References (14)

1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M. 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7:e35671. doi:10.1371/journal.pone.0035671.
2. World Health Organization. 2005. Regional strategic framework for elimination of kala-azar from the South-East Asia Region (2005-2015). World Health Organization Regional Office for South-East Asia, New Delhi, India. http://apps.searo.who.int/pds_docs/B0211.pdf.
3. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC, Chakravarty J. 2012. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin. Infect. Dis. 55:543-550.
4. Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TP, Beijnen JH, Vanaerschot M, Decuypere S, Dhakal SS, Das ML, Karki P, Singh R, Boelaert M, Dujardin JC. 2013. Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin. Infect. Dis. 56: 1530-1538.
5. Rijal S, Yardley V, Chappuis F, Decuypere S, Khanal B, Singh R, Boelaert M, De Doncker S, Croft S, Dujardin JC. 2007. Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome? Microbes Infect. 9:529-535.
6. Prajapati VK, Sharma S, Rai M, Ostyn B, Salotra P, Vanaerschot M, Dujardin JC, Sundar S. 26 August 2013. In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis. Am. J. Trop. Med. Hyg. [Epub ahead of print.] doi:10.4269/ajtmh.13-0096.
7. Ouakad M, Vanaerschot M, Rijal S, Sundar S, Speybroeck N, Kestens L, Boel L, De Doncker S, Maes I, Decuypere S, Dujardin JC. 2011. Increased metacyclogenesis of antimony-resistant Leishmania donovani clinical lines. Parasitology 138:1392-1399.
8. Vanaerschot M, Maes I, Ouakad M, Adaui V, Maes L, De Doncker S, Rijal S, Chappuis F, Dujardin JC, Decuypere S. 2010. Linking in vitro and in vivo survival of clinical Leishmania donovani strains. PLoS One 5:e12211. doi:10.1371/journal.pone.0012211.
9. da Silva R, Sacks DL. 1987. Metacyclogenesis is a major determinant of Leishmania promastigote virulence and attenuation. Infect. Immun. 55: 2802-2806.
10. Kulshrestha A, Bhandari V, Mukhopadhyay R, Ramesh V, Sundar S, Maes L, Dujardin JC, Roy S, Salotra P. 2013. Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani. Parasitol. Res. 112:825-828.
11. Saraiva EM, Pinto-da-Silva LH, Wanderley JL, Bonomo AC, Barcinski MA, Moreira ME. 2005. Flow cytometric assessment of Leishmania spp. metacyclic differentiation: validation by morphological features and specific markers. Exp. Parasitol. 110:39-47.
12. Haldar AK, Yadav V, Singhal E, Bisht KK, Singh A, Bhaumik S, Basu R, Sen P, Roy S. 2010. Leishmania donovani isolates with antimony-resistant but not-sensitive phenotype inhibit sodium antimony gluconate-induced dendritic cell activation. PLoS Pathog. 6:e1000907. doi:10.1371/ journal.ppat.1000907.
13. Downing T, Imamura H, Decuypere S, Clark TG, Coombs GH, Cotton JA, Hilley JD, De Doncker S, Maes I, Mottram JC, Quail MA, Rijal S, Sanders M, Schönian G, Stark O, Sundar S, Vanaerschot M, Hertz-Fowler C, Dujardin JC, Berriman M. 2011. Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res. 21: 2143-2156.
14. Vanaerschot M, Decuypere S, Berg M, Roy S, Dujardin JC. 6 September 2012. Drug-resistant microorganisms with a higher fitness- can medicines boost pathogens? Crit. Rev. Microbiol. [Epub ahead of print.] doi: 10.3109/1040841X.2012.716818.